- Home
- FMN vs CLLS Comparison
FMN vs CLLS Comparison
Compare FMN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMN
- CLLS
- Stock Information
- Founded
- FMN 2002
- CLLS 1999
- Country
- FMN United States
- CLLS France
- Employees
- FMN N/A
- CLLS N/A
- Industry
- FMN Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- FMN Finance
- CLLS Health Care
- Exchange
- FMN Nasdaq
- CLLS Nasdaq
- Market Cap
- FMN 127.6M
- CLLS 148.1M
- IPO Year
- FMN N/A
- CLLS 2007
- Fundamental
- Price
- FMN $11.28
- CLLS $1.53
- Analyst Decision
- FMN
- CLLS Buy
- Analyst Count
- FMN 0
- CLLS 3
- Target Price
- FMN N/A
- CLLS $7.00
- AVG Volume (30 Days)
- FMN 22.8K
- CLLS 114.3K
- Earning Date
- FMN 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- FMN 3.86%
- CLLS N/A
- EPS Growth
- FMN N/A
- CLLS N/A
- EPS
- FMN N/A
- CLLS N/A
- Revenue
- FMN N/A
- CLLS $36,042,000.00
- Revenue This Year
- FMN N/A
- CLLS $387.77
- Revenue Next Year
- FMN N/A
- CLLS $11.14
- P/E Ratio
- FMN N/A
- CLLS N/A
- Revenue Growth
- FMN N/A
- CLLS 46.96
- 52 Week Low
- FMN $9.09
- CLLS $1.41
- 52 Week High
- FMN $11.31
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- FMN 60.55
- CLLS 45.06
- Support Level
- FMN $11.01
- CLLS $1.51
- Resistance Level
- FMN $11.30
- CLLS $1.62
- Average True Range (ATR)
- FMN 0.09
- CLLS 0.09
- MACD
- FMN 0.02
- CLLS 0.01
- Stochastic Oscillator
- FMN 72.97
- CLLS 29.17
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers.. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.